Insider Buying: Bolt Biotherapeutics (NASDAQ:BOLT) Major Shareholder Purchases $319,000.00 in Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) major shareholder Coastlands Capital Lp purchased 50,000 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were acquired at an average price of $6.38 per share, with a total value of $319,000.00. Following the completion of the acquisition, the insider owned 462,416 shares in the company, valued at approximately $2,950,214.08. This trade represents a 12.12% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Bolt Biotherapeutics Trading Up 0.9%

Shares of BOLT stock traded up $0.06 during trading hours on Tuesday, hitting $6.49. 11,797 shares of the company were exchanged, compared to its average volume of 92,139. The firm has a market cap of $12.50 million, a P/E ratio of -0.39 and a beta of 0.85. Bolt Biotherapeutics, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $7.78. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. The company has a 50 day simple moving average of $4.45 and a two-hundred day simple moving average of $4.52.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. Equities analysts anticipate that Bolt Biotherapeutics, Inc. will post -11.10 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd bought a new position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics comprises 0.0% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 25th biggest position. Nan Fung Group Holdings Ltd owned approximately 0.26% of Bolt Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. 86.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Bolt Biotherapeutics currently has an average rating of “Hold” and a consensus price target of $14.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.